Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149116 | PMC |
| http://dx.doi.org/10.1111/bjh.18076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
Kidney360
July 2023
Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
The underlying mechanisms of disease in sickle cell disease (SCD) contribute to a multifaceted nephropathy, commonly manifested as albuminuria. In severe SCD genotypes ( e.g.
View Article and Find Full Text PDFVoxelotor and albuminuria in adults with sickle cell anaemia.
Br J Haematol
June 2022
Division of Hematology and Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.
The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
Int J Clin Pract
June 2021
Department of Medical Pharmacology, Faculty of Medicine, Inonu University, Malatya, Turkey.
Objective: Sickle cell anaemia (SCA), an inherited chronic hematological disease affecting hundreds of thousand people worldwide, causes significant morbidity and reduced life expectancy about two or three decades. This study aimed to conduct a meta-analysis of the efficacy of voxelotor, 900 mg in patients with SCA.
Methods: The research protocol was registered at the International Register of Prospective Systematic Reviews (PROSPERO), under the registration number: CRD42020147796.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!